Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Stolarski

Adult Reconstructive Orthopaedic Surgery Sarasota, FL Medical Doctor

NPI 1164461406 CMS profile 7331

6050 Cattleridge Blvd Ste 201, Sarasota, FL 34232

Open in the dashboard

General payments

$444,726

189 records reported · program years 2019–2025

Research payments

$112,708

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,206,777 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Edward Stolarski of Sarasota, FL is reported in the CMS Open Payments database as having received $444,726 across 189 general payments and $112,708 in research payments paid to them. Separately, studies naming them as principal investigator received $2,206,777 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,590 12
2025 Research $83,598 6
2024 General $172,696 11
2023 General $24,321 30
2022 General $51,472 21
2022 Research $4,880 1
2021 General $70,285 51
2021 Research $24,230 2
2020 General $51,555 26
2019 General $48,808 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Stolarski
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Edward Stolarski were reported at $25,590. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Edward Stolarski Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $48,808 $1,416 $292–$9,336 $163
2020 $51,555 $647 $141–$6,474 $114
2021 $70,285 $1,073 $211–$6,497 $132
2022 $51,472 $1,217 $236–$6,299 $149
2023 $24,321 $1,082 $246–$6,818 $160
2024 $172,696 $1,575 $323–$8,944 $164
2025 $25,590 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medacta USA, Inc. $262,186 72 payments
  2. Canary Medical USA LLC $150,527 2 payments
  3. Zimmer Biomet Holdings, Inc. $27,517 65 payments
  4. Corentec America,Inc. $1,500 1 payment
  5. Stryker Corporation $877 16 payments
  6. NextStep Arthropedix, LLC $748 2 payments
  7. Smith+Nephew, Inc. $348 5 payments
  8. Heraeus Medical, LLC. $240 7 payments
  9. Flexion Therapeutics, Inc. $193 2 payments
  10. Biocomposites Inc $144 1 payment
  11. Other $448 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $249,246 43 payments
  2. Consulting Fee $184,938 23 payments
  3. Food and Beverage $5,735 97 payments
  4. Travel and Lodging $4,769 25 payments
  5. Long term medical supply or device loan $37 1 payment
Products named General payments · program years 2019–2025
  1. MASTERLOC $152,548 16 payments
  2. M-VIZION Hip $53,827 25 payments
  3. M-Vizion Orthopedics/Orthopedic Surgery $25,122 4 payments
  4. M-Vizion Femoral Revision System $21,162 4 payments
  5. ROSA-Knee $9,200 12 payments
  6. Avenir Hips $6,000 3 payments
  7. Avenir Hips $5,712 6 payments
  8. G7 $5,625 3 payments
  9. AMISTEM $2,353 11 payments
  10. ROSA $1,873 6 payments
  11. Other $14,439 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Canary Medical USA LLC $83,598 6 payments
  2. Medacta USA, Inc. $29,110 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,144

Median for Orthopedic Surgery: 203

Drug cost

$5,400

Median for Orthopedic Surgery: $1,433

Branded share of claims

1.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 149 $2,818
Amoxicillin Generic 593 $1,015
Clindamycin Hcl Generic 113 $345
Meloxicam Generic 118 $333
Methylprednisolone Generic 51 $283
Cephalexin Generic 33 $203
Ondansetron Hcl Generic 20 $121
Mupirocin Generic 16 $103
Azithromycin Generic 14 $77
Ciprofloxacin Hcl Generic 24 $75

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$1,586,095

Of which drugs: $234,064

Medicare patients

2,955

Average age 76

Services billed

27,205

1,805 women, 1,150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Osteoporosis 21%
Diabetes 20%
Atrial fibrillation 20%
Chronic kidney disease 20%
Depression 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 199 296 $160,445
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 19 1,490 $20,175
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 17 40 $16,159
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 16 1,056 $14,480
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 24 142 $13,373
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 1,015 9,033 $6,526

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

198 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record